Cart
sales@molnova.com
AZD8542
CAS No. 1126366-36-6
AZD8542( —— )
Catalog No. M34171 CAS No. 1126366-36-6
AZD8542 is an antagonist of Smoothened (SMO) with potential as an [oncology therapeutic].
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 613 | In Stock |
|
| 10MG | 847 | In Stock |
|
| 25MG | 1311 | In Stock |
|
| 50MG | 1655 | In Stock |
|
| 100MG | 2186 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAZD8542
-
NoteResearch use only, not for human use.
-
Brief DescriptionAZD8542 is an antagonist of Smoothened (SMO) with potential as an [oncology therapeutic].
-
DescriptionAZD8542 is an antagonist of Smoothened (SMO), playing an important role in oncology. AZD8542 is a Hedgehog (Hh) pathway antagonist on tumor progression with an emphasis on the role of the stroma compartment.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetHedgehog (Hh)
-
RecptorHedgehog/Smoothened | Smo
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1126366-36-6
-
Formula Weight412.48
-
Molecular FormulaC25H24N4O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NC1=CC(C=2N=CN(C2)C)=C(C=C1C)C)C3=CC=C(OCC4=NC=CC=C4)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Rosa F. Hwang, INHIBITION OF THE HEDGEHOG PATHWAY TARGETS THE TUMOR-ASSOCIATED STROMA IN PANCREATIC CANCER. Mol Cancer Res. 2012 Sep; 10(9): 1147–1157.
molnova catalog
related products
-
Purmorphamine
Purmorphamine, which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM in HEK293T cell and also is an inducer of osteoblast differentiation with EC50 of 1 μM.
-
Ciliobrevin A
A small molecule Hedgehog pathway inhibitor (IC50=7 uM) that acts downstream of Su(fu) to modulate Gli processing, activation or trafficking.
-
BIO-acetoxime
BIO-acetoxime is a potent dual GSK3α/β inhibitor with IC50 of 10 nM, >240-fold selectivity over CDK5/p25, CDK2/cyclin A and CDK1/cyclin B.
